Citations

Clear

29 citation(s) found for "Merlo, M".

Significance of Common Genetic Variants Associated with Non-Ischaemic Cardiomyopathy in the General Population
Paldino, Alessia , Figueiral, Marta , Vyas, Hridyanshu , Jenkins, Gregory D. , Batzler, Anthony , Klee, Eric W. , Rodeheffer, Richard J. , Redfield, Margaret M. , Burnett, John C. , Lopez‐Jimenez, Francisco, Sinagra, Gianfranco, Merlo, Marco, Pereira, Naveen L. , Jenkins, Gregory, Medina Inojosa, Jose R, Pereira, Naveen L , Scott, Christopher G. , Medina‐Inojosa, José R. , López-Jiménez, Francisco , Sinagra, Gianfranco , Merlo, Marco

Mayo Clinic

European Journal of Heart Failure | June 23, 2025 | Volume: 27 | Issue: 12 | Pages: 3235-3242

10.1002/ejhf.3724 | PMID 40549485 Get It

ABSTRACT Aims Common genetic variants have been linked to an increased risk of non-ischaemic cardiomyopathy (NICM). The primary objective of this study was to evaluate the significance of these variants in a general population. Methods and results Thirteen NICM risk alleles, previously validated by meta-analyses of case-control genetic association studies, were used to determine genetic risk (GR) in a large, unselected cohort (n = 1897) of Olmsted County residents aged >45 years. Clinical and echocardiographic data, with biomarkers, were correlated with this NICM-GR over a median of 16 years of follow-up (interquartile range [IQR] 15–17). There were no significant differences between the study population quartiles, based on NICM-GR, in terms of age (median 61.6 [IQR 53.6–70.4]), sex (48% male), and cardiovascular risk factors. A significant correlation was detected by specific linear-regression models between NICM-GR and left ventricular (LV) ejection-fraction (beta [standard error]: −2.68 [0.68], p < 0.001), LV end-systolic-diameter (0.22 [0.06], p < 0.001), and LV end-diastolic-diameter (0.14 [0.06], p = 0.01). During follow-up, 46 subjects developed NICM. Using a 3:1 matched-cohort of non-NICM versus NICM patients, linear-regression analysis found a significant correlation between NICM-GR and NICM development (odds ratio 2.27, 95% confidence interval 1.06–4.85, p = 0.03). There was no significant association between these variants and heart failure biomarkers (aldosterone, natriuretic peptides, ST2, galectin-3). Conclusions The NICM-GR correlates with LV function and dimension, and subsequent development of NICM in the general population. The lack of correlation of these variants with cardiovascular risk factors and the renin–angiotensin–aldosterone axis or natriuretic peptides suggest different biological mechanisms involved. These findings support the need to explore newer pathophysiologic pathways in the development of NICM.
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Michieli, Laura De , Guida, Gianluigi , Saturi, Giulia , Sena, Guido De , Capovilla, Teresa Maria , Cantone, Anna , Cianca, Alessandro , Lupi, Alessandro , Porcari, Aldostefano , Vergaro, Giuseppe , Albertini, Riccardo, Serenelli, Matteo , Merlo, Marco , Longhi, Simone , Marra, Martina Perazzolo , Iliceto, Sabino , Jaffe, Allan S. , Milani, Paolo , De Michieli, Laura , Guida, Gianluigi , Saturi, Giulia , Sena, Giuseppe , Capovilla, Teresa Maria , Cantone, Anna , Porcari, Aldostefano , Tini, Giacomo , Vergaro, Giuseppe , Cappelli, Francesco , Bianco, Matteo , Mussinelli, Roberta , Musumeci, Beatrice , Perlini, Stefano , Merlo, Marco , Longhi, Simone , Sinagra, Gianfranco , Perazzolo Marra, Martina , Iliceto, Sabino , Jaffe, Allan S. , Palladini, Giovanni , Cipriani, Alberto , Milani, Paolo , Sinigiani, Giulio , Bianco, Matteo , Mussinelli, Roberta , Perlini, Stefano , Palladini, Giovanni

Mayo Clinic

Circulation: Heart Failure | May 15, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.125.012816 | PMID 40371473 Get It

BACKGROUND: Thresholds to define prognosis with hs-cTnI (high-sensitivity cardiac troponin I) have not been systematically addressed in wild-type transthyretin amyloid cardiomyopathy, in part because of the multiplicity of hs-cTnI assays. The aims of this study were: first, to assess the prognostic performance of hs-cTnI measured with different assays in patients with wild-type transthyretin amyloid cardiomyopathy and, second, to identify assay-specific hs-cTnI thresholds for prognosis that could be integrated into staging systems for risk stratification. METHODS: Observational multicenter study of stable wild-type transthyretin amyloid cardiomyopathy patients from different cohorts using the Abbott Architect Stat hs-cTnI assay and the Beckman Coulter Access hs-cTnI assay (testing cohorts) and the Siemens Centaur XPT hs-cTnI assay (validation cohort). Outcome was all-cause mortality. RESULTS: In the Abbott cohort (n=136; median follow-up 22 [13–41] months; 31 [23%] deaths) and Beckman cohort (n=98; median follow-up 19 [12–28] months; 16 [16%] deaths), natural log-transformed hs-cTnI was an independent predictor of mortality (age- and sex-adjusted hazard ratio, 1.62 [95% CI, 1.11–2.35]; P =0.012 and 2.47 [95% CI, 1.48–4.14]; P <0.001, respectively). The best hs-cTnI threshold for 18-month mortality of the combined Abbott/Beckman cohorts (n=234) was 81 ng/L, rounded to 80 ng/L for simplicity of clinical use. A 2-variable staging system (based on the Mayo Clinic system) using hs-cTnI (>80 ng/L) and NPs (natriuretic peptides; NT-proBNP [N-terminal pro-B-type natriuretic peptide] >3000 ng/L or BNP [B-type natriuretic peptide] >250 ng/L) identified 3 groups with progressively worse prognosis. The staging system (using hs-cTnI >80 ng/L and NT-proBNP>3000 ng/L) was then applied to an independent cohort evaluated with the hs-cTnI Siemens assay (n=345, median follow-up 32 [24-42] months, 119 [34%] deaths). The significant differences between the groups were maintained. CONCLUSIONS: In patients with wild-type transthyretin amyloid cardiomyopathy, hs-cTnI is a strong and independent predictor of mortality. A threshold of hs-cTnI of 80 ng/L for these 3 assays provides effective risk stratification alone and in a staging system with NP.
Abstract 4141605: Genetic Determinant for Prognosis of Dilated Cardiomyopathy: The role of NAV3 in Cardiac Fibrosis
Wang, Min , Wang, Li , Seal, Mayah, McNamara, Dennis M. , Barlera, Simona, Merlo, Marco , Krejčí, Jan , Weinshilboum, Richard M. , Pereira, Naveen L. , Ghazal, Rachad , Seal, Mayah, Nguyen, Thanh Thanh L. , Pileggi, Silvana , Mestroni, Luisa , Sinagra, Gianfranco , Pinet, F , Liu, Duan , Weinshilboum, Richard M.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4141605 Get It

Background: Dilated Cardiomyopathy (DCM) is a major cause of heart failure (HF) and carries a high mortality rate. Drug treatment response for DCM-related HF patients is highly variable, with some patients having no response. A pharmacogenomic approach, genome-wide association study (GWAS) followed by biologically functional validation, can potentially identify genetic determinants of prognosis in DCM and might provide insight into novel biology of DCM pharmacotherapy. Methods: A GWAS was performed using DNA from 686 patients with recent onset DCM who were on standard HF therapy using change in left ventricular ejection fraction (LVEF) at a median of 6 months after initial diagnosis. Cultured human cardiac fibroblasts (HCFs) were used to functionally validate the GWAS findings in vitro . RNA-seq followed by pathway analysis after NAV3 knock-down (KD) using siRNA in HCFs were performed to explore potential biological mechanisms. Results: A genetic variant, rs11105445(G>A), identified from the GWAS, mapping to the neuron navigator 3 (NAV3) gene (rs11105445, p=2.37E-07; beta 2.74 ± 0.53) was associated with improvement in LVEF. Functional genomic experiments demonstrated that, both in LV tissue and in cultured fibroblasts, the minor allele A was associated with decreased transcription of NAV3 (pvalue: 0.0335 and 0.0432) suggesting that ↓NAV3 expression might be associated with improvement in LVEF. TGF-β1 can induce HCF transdifferentiation into myofibroblasts and we demonstrate that it also increases NAV3 expression. NAV3 KD which mimics the GWAS variant significantly suppressed TGF-β1 induced HCF transdifferentiation demonstrated by decreased expression of α-smooth muscle actin (ACTA2) and collagen I (COL1A1). RNA-seq after NAV3 KD followed by pathway analysis suggested that NAV3 exerted its effect by regulating ECM and cell cycle processes, especially G1/S transition. We demonstrate that NAV3 KD suppressed TGF-β1 induced G1/S arrest by regulating CDK4, CDK6 and INK4B (cyclin-dependent kinase inhibitor 2B/P15, CDK4 inhibitor). Conclusion: Decreased expression of NAV3 is associated with myocardial recovery in DCM, most likely due to its role in suppressing HCF differentiation by regulating TGF-β1 induced G1/S arrest. The role of NAV3 as a novel therapeutic target in DCM needs to be explored.
Predictors of hypercontractile heart phenotype in patients with chronic coronary syndromes or heart failure
Cortigiani, Lauro , Souto, Germán, Djordjevic‐Dikic, Ana , Reisenhofer, Barbara, Boshchenko, A , Rigo, F , Merli, Elisa , Lisi, Matteo , Simova, Iana , Pitino, Annalisa , Nes, Michele De, Tripepi, Giovanni Luigi, Yin, Lixue , Picano, Eugenio , Boshchenko, Alla , Wang, Yi , Ciampi, Quirino , Zagatina, A , Kasprzak, Jarosław D. , Wierzbowska‐Drabik, Karina , Haberka, Maciej , Lowenstein, Jorge , Arbucci, Rosina , Haber, Diego M. Lowenstein, Marconi, Sofia, Merlo, Pablo , Barral, Patricia, Ryabova, Tamara , Rodríguez‐Zanella, Hugo , D’Andrea, Antonello , Gaibazzi, Nicola , Barbieri, Andréa , Morrone, Doralisa , Citro, Rodolfo , Carerj, Scipione , Pepi, Mauro , Pellikka, Patricia A. , group, on behalf of the Stress Echo 2030 study

Mayo Clinic

No container title available | June 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4476811/v1 Get It

Abstract Background Hypercontractile phenotype (HP) of the left ventricle (LV) is an actionable therapeutic target in patients with chronic coronary syndromes (CCS) or heart failure (HF), but its clinical recognition remains difficult. Objectives To assess the clinical variables associated with the HP. Methods In a prospective, observational, multicenter study, we recruited 5,122 patients (age 65 ± 11 years, 2974 males, 58%) with CCS and/or HF with preserved ejection fraction (EF). Systolic blood pressure (SBP) was measured. We assessed wall motion score index (WMSI), LV end-diastolic volume (EDV), end-systolic volume (ESV), EF, force (SBP/ESV), stroke volume (SV), arterial elastance (SBP/SV), and ventricular-arterial coupling (VAC, as SV/ESV). Univariable and multivariable logistic regression analysis assessed independent factors associated with the highest force sextile. Results For all the studied patients, force was 4.51 ± 2.11 mmHg/ml, with the highest sextile (Group 6) > 6.36 mmHg/ml. By multivariable logistic regression model, the highest sextile of force was associated with age > 65 years (OR 1.62, 95% CI 1.36–1.93, p < 0.001), hypertension (OR 1.76, 95% CI 1.40–2.21, p < 0.001), female sex (OR 4.52, 95% CI 3.77–5.42, p < 0.001), absence of beta-blocker therapy (OR 1.41, 95% CI 1.16–1.68), rest SBP ≥ 160 mmHg (OR 2.81, 95% CI 2.21–3.56, p < 0.001), high heart rate (OR 2.08, 95% CI 1.61–2.67, p < 0.001), and absence of prior myocardial infarction (OR 1.34, 95% CI 1.07–1.68, p = 0.012). Patients in the highest sextile of force showed lower values of WMSI, SV, EDV, and ESV, and higher values of arterial elastance and VAC. Conclusions HP of the LV with high force was clinically associated with advanced age, female sex, high resting SBP, and the absence of 𝛽-blocker therapy. By transthoracic echocardiography, HP was associated with a small heart with reduced EDV, reduced SV despite high EF, and higher arterial elastance.
Role of Arrhythmic Phenotype in Prognostic Stratification and Management of Dilated Cardiomyopathy
Setti, Martina , Merlo, Marco , Gigli, Marta , Munaretto, L, Paldino, Alessia , Gava, Carola Pio Loco Detto , Medo, Kristen , Gregorio, Caterina , Graw, Sharon , Castrichini, Matteo , Cannatà, Antonio , Ferro, Matteo Dal , Taylor, Matthew R.G. , Mestroni, Luisa , Mestroni, Luisa , Castrichini, Matteo , Medo, Kristen , Taylor, Matthew R G , Cannatà, Antonio , Gregorio, Caterina , Stolfo, Davide , Luca, Antonio De , Ribichini, Flavio Luciano , Sinagra, Gianfranco

Mayo Clinic

European Journal of Heart Failure | February 26, 2024 | Volume: 26 | Issue: 3 | Pages: 581-589

10.1002/ejhf.3168 | PMID 38404225 Get It

Abstract Aims Dilated cardiomyopathy (DCM) with arrhythmic phenotype combines phenotypical aspects of DCM and predisposition to ventricular arrhythmias, typical of arrhythmogenic cardiomyopathy. The definition of DCM with arrhythmic phenotype is not universally accepted, leading to uncertainty in the identification of high-risk patients. This study aimed to assess the prognostic impact of arrhythmic phenotype in risk stratification and the correlation of arrhythmic markers with high-risk arrhythmogenic gene variants in DCM patients. Methods and results In this multicentre study, DCM patients with available genetic testing were analysed. The following arrhythmic markers, present at baseline or within 1 year of enrolment, were tested: unexplained syncope, rapid non-sustained ventricular tachycardia (NSVT), ≥1000 premature ventricular contractions/24 h or ≥50 ventricular couplets/24 h. LMNA, FLNC, RBM20, and desmosomal pathogenic or likely pathogenic gene variants were considered high-risk arrhythmogenic genes. The study endpoint was a composite of sudden cardiac death and major ventricular arrhythmias (SCD/MVA). We studied 742 DCM patients (45 ± 14 years, 34% female, 410 [55%] with left ventricular ejection fraction [LVEF] &lt;35%). During a median follow-up of 6 years (interquartile range 1.6–12.1), unexplained syncope and NSVT were the only arrhythmic markers associated with SCD/MVA, and the combination of the two markers carried a significant additive risk of SCD/MVA, incremental to LVEF and New York Heart Association class. The probability of identifying an arrhythmogenic genotype rose from 8% to 30% if both early syncope and NSVT were present. Conclusion In DCM patients, the combination of early detected NSVT and unexplained syncope increases the risk of life-threatening arrhythmic outcomes and can aid the identification of carriers of malignant arrhythmogenic genotypes.
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe
Carrick, Richard , Marco, Corrado De , Gasperetti, Alessio , Bosman, Laurens P. , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Pendleton, Catherine, Tichnell, Crystal , Tandri, Harikrishna , Zeppenfeld, Katja , Wilde, Arthur A.M. , Davies, Brianna , Seifer, Colette , Roberts, Jason D. , MacIntyre, Ciorsti, Alqarawi, Wael , Cutler, Michael J. , Targetti, Mattia , Calò, Leonardo , Vitali, Francesco , Compagnucci, Paolo , Cappelletto, Chiara, Duru, Fırat , Jensen, Henrik Kjærulf , Svensson, Anneli , Dahlberg, Pia , Hasselberg, Nina E. , Marco, Andrea Di , Jordà, Paloma , Weidmann, Zoraida Moreno , Borowiec, Karolina , Delinière, Antoine , Tintelen, J. Peter van , Olivotto, Iacopo , Saguner, Ardan M. , Cox, Moniek G.P.J. , Merlo, Marco , Riele, Anneline S.J.M. te , Wu, Kathérine C. , Calkins, Hugh , James, Cynthia A. , Cadrin‐Tourigny, Julia , Carrick, Richard T , De Marco, Corrado , Gourraud, Jean-Baptiste , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Zeppenfeld, Katja , Davies, Brianna , Alqarawi, Wael , Bertini, Matteo , Compagnucci, Paolo , Cappelletto, Chiara , Stolfo, Davide , Duru, Firat , Di Marco, Andrea , Arbelo, Elena , Delinière, Antoine , Saguner, Ardan M , Merlo, Marco , Krahn, Andrew D , Te Riele, Anneline S J M , Calkins, Hugh , James, Cynthia A , Cadrin-Tourigny, Julia , van Tintelen, J Peter , Olivotto, Iacopo , Jensen, Henrik Kjærulf , Gourraud, Jean‐Baptiste , Healey, Jeff S. , Tadros, Rafik , Casella, Michela , Russo, Antonio Dello , Luca, Antonio De , Arbelo, Elena , Biernacka, Elżbieta Katarzyna , Platonov, Pyotr G. , Haugaa, Kristina H. , Tondo, Claudio , Krahn, Andrew D.

Mayo Clinic

European Heart Journal | January 10, 2024 | Volume: 45 | Issue: 7 | Pages: 538-548

10.1093/eurheartj/ehad799 | PMID 38195003 Get It

Abstract Background and Aims Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. Methods This was a retrospective analysis of ARVC patients without prior VA enrolled in clinical registries from 11 countries throughout Europe and North America. Patients were classified according to whether they received treatment in North America or Europe and were further stratified by baseline predicted VA risk into low- (&lt;10%/5 years), intermediate- (10%–25%/5 years), and high-risk (&gt;25%/5 years) groups. Differences in ICD implantation and survival free from sustained VA events (including appropriate ICD therapy) were assessed. Results One thousand ninety-eight patients were followed for a median of 5.1 years; 554 (50.5%) received a primary prevention ICD, and 286 (26.0%) experienced a first VA event. After adjusting for baseline risk factors, North Americans were more than three times as likely to receive ICDs {hazard ratio (HR) 3.1 [95% confidence interval (CI) 2.5, 3.8]} but had only mildly increased risk for incident sustained VA [HR 1.4 (95% CI 1.1, 1.8)]. North Americans without ICDs were at higher risk for incident sustained VA [HR 2.1 (95% CI 1.3, 3.4)] than Europeans. Conclusions North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.
Abstract 16898: Myocardial Recovery Associated Gene Cdcp1 Expression Attenuates Cardiac Fibrosis in a Pressure Over-Load Mouse Model
Wang, Min , Vyas, Hridyanshu , Roos, Carolyn M, Huang, Runqing, Sahni, Jyotan , McNamara, Dennis M. , Barlera, Simona, Merlo, Marco , Chaloupka, Anna , Krejčí, Jan , Weinshilboum, Richard M. , Pereira, Naveen L. , Liu, Duan , Pileggi, Silvana , Mestroni, Luisa , Sinagra, Gianfranco , Pinet, F , Groote, Pascal de , Weinshilboum, Richard M. , Miller, Jordan D.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16898 Get It

Background: We have previously demonstrated by performing a genome-wide association study that a genetic locus resulting in ↓CDCP1 expression was associated with myocardial recovery in patients with dilated cardiomyopathy (DCM). We have subsequently shown that ↓CDCP1 decreases human cardiac fibroblast proliferation in vitro , however, its potential role in modulating cardiac fibrosis and function in vivo is unknown. Methods: A Cdcp1 knock-out (KO) mouse was generated on FVB/NJ background. Angiotensin II/Phenylephrine (AngII/PE) or saline was infused by an osmotic pump into mice ( Cdcp1 KO n=20; wild type/wt n=18) for 4 weeks. Echocardiography was performed at 0 and 4 weeks. Picrosirius red (PSR) staining was performed on cross-sectional heart tissue to identify cardiac fibrosis, which was quantified, using ImageJ software, as a percentage of left ventricular (LV) area stained by PSR. Results: LV mass index (LVMI) significantly increased in AngII/PE wt mice as compared to saline wt (figure a. 3.65±0.15 mg/g vs 3.05±0.17mg/g, p=0.01), however, AngII/PE Cdcp1 KO mice had significantly decreased LVMI as compared to AngII/PE wt mice (figure a. 3.17±0.09 mg/g vs 3.65±0.15 mg/g, p=0.01). In addition, fractional shortening trended higher in AngII/PE Cdcp1 KO mice as compared to AngII/PE wt mice (figure b. 50.36±2.06% vs 45.48±1.43%, p=0.07). Extent of cardiac fibrosis was significantly higher in AngII/PE wt mice as compared to saline wt (figure c. 15.79±0.49% vs 7.93±0.39%, p<0.0001), however AngII/PE Cdcp1 KO mice had significantly reduced cardiac fibrosis as compared to AngII/PE wt mice (figure c. 9.41±0.43%, p<0.0001). Conclusions: CDCP1 KO significantly reduces pressure over-load induced LV hypertrophy and cardiac fibrosis. Its role as a novel therapeutic target in attenuating fibrosis and improving cardiac function in DCM needs to be further explored.
Abstract 15195: Utility of a Polygenic Risk Score for Dilated Cardiomyopathy in the General Population
Paldino, Alessia , Figueiral, Marta , Vyas, Hridyanshu , Jenkins, Gregory D. , Klee, Eric W. , Rodeheffer, Richard J. , Redfield, Margaret M. , Burnett, John C. , Merlo, Marco , Pereira, Naveen L. , Scott, Christopher G. , Medina‐Inojosa, José R. , López-Jiménez, Francisco , Sinagra, Gianfranco

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.15195 Get It

Introduction: Common genetic variation has been linked to an increased risk of developing dilated cardiomyopathy (DCM). However, the phenotypic profile, outcomes, and biological mechanisms by which such genetic background may predispose individuals to DCM are still unknown. Hypothesis: The primary objectives of this study were to develop a DCM polygenic risk score (PRS) based on prior case control-DCM GWAS and to apply this PRS to a well clinical characterized general population. Methods: The DCM-PRS was derived from 13 DCM risk alleles that were assayed in an unselected cohort (n=1897) of unrelated Olmsted County residents age >45 years who did not have a history of heart failure (HF) or CM and underwent physical examination, echocardiography, and blood analyses. Results: The entire population was equally divided into quartiles based on the DCM-PRS. No significant differences were present in terms of age (median 62 years) and sex (48% male). However, a significant correlation was detected between the DCM-PRS and left ventricle ejection fraction (LVEF) (Beta: -2.68, p<0.001), LV end-systolic diameter (Beta: 0.22, p<0.001), and LV end-diastolic diameter (Beta: 0.14, p=0.01). During a follow-up of 16 years (IQR: 15-17), 47 subjects developed DCM. Using a 3:1 non-DCM vs DCM matched cohort, a logistic regression analysis, found a significant correlation between median DCM-PRS and DCM development [OR=2.27 (1.06, 4.85), p=0.03]. However, there was no association between the DCM-PRS and HF biomarkers (aldosterone, natriuretic peptides, ST2, Galectin-3). Conclusions: DCM-PRS correlates with decreased LVEF, increased LV dimensions, and DCM development in a general population without significant differences in baseline clinical features. The absence of correlation between the DCM-PRS and available HF biomarkers suggests that this genetic background affects LV traits and DCM development independent of these biological mechanisms.
Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis
Liu, Duan , Wang, Min , Murthy, Vishakantha , McNamara, Dennis M. , Nguyen, Thanh Thanh L. , Philips, Trudy Janice , Vyas, Hridyanshu , Gao, Huanyao , Sahni, Jyotan , Starling, Randall C. , Skime, Michelle , Batzler, Anthony , Jenkins, Gregory D. , Barlera, Simona, Pileggi, Silvana , Mestroni, Luisa , Merlo, Marco , Pinet, F , Krejčí, Jan , Chaloupka, Anna , Groote, Pascal de , Tschumperlin, Daniel J. , Weinshilboum, Richard M. , Pereira, Naveen L. , Philips, Trudy J, Cooper, Leslie T , Skime, Michelle K , Batzler, Anthony , Pileggi, Silvana , Mestroni, Luisa , Sinagra, Gianfranco , Pinet, Florence , Krejčí, Jan , Chaloupka, Anna , Miller, Jordan D. , de Groote, Pascal , Pereira, Naveen L , Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Cooper, Leslie T. , Weinshilboum, Richard M.

Mayo Clinic

Circulation Research | October 6, 2023 | Volume: 133 | Issue: 10 | Pages: 810-825

10.1161/circresaha.123.323200 | PMID 37800334 Get It

BACKGROUND: Dilated cardiomyopathy (DCM) is a major cause of heart failure and carries a high mortality rate. Myocardial recovery in DCM-related heart failure patients is highly variable, with some patients having little or no response to standard drug therapy. A genome-wide association study may agnostically identify biomarkers and provide novel insight into the biology of myocardial recovery in DCM. METHODS: A genome-wide association study for change in left ventricular ejection fraction was performed in 686 White subjects with recent-onset DCM who received standard pharmacotherapy. Genome-wide association study signals were subsequently functionally validated and studied in relevant cellular models to understand molecular mechanisms that may have contributed to the change in left ventricular ejection fraction. RESULTS: The genome-wide association study identified a highly suggestive locus that mapped to the 5′-flanking region of the CDCP1 (CUB [complement C1r/C1s, Uegf, and Bmp1] domain containing protein 1) gene (rs6773435; P =7.12×10 −7 ). The variant allele was associated with improved cardiac function and decreased CDCP1 transcription. CDCP1 expression was significantly upregulated in human cardiac fibroblasts (HCFs) in response to the PDGF (platelet-derived growth factor) signaling, and knockdown of CDCP1 significantly repressed HCF proliferation and decreased AKT (protein kinase B) phosphorylation. Transcriptomic profiling after CDCP1 knockdown in HCFs supported the conclusion that CDCP1 regulates HCF proliferation and mitosis. In addition, CDCP1 knockdown in HCFs resulted in significantly decreased expression of soluble ST2 (suppression of tumorigenicity-2), a prognostic biomarker for heart failure and inductor of cardiac fibrosis. CONCLUSIONS: CDCP1 may play an important role in myocardial recovery in recent-onset DCM and mediates its effect primarily by attenuating cardiac fibrosis.
CME-Certified Microlearning Platform Successful in Improving Knowledge on the Use of Preventive Migraine Therapies Among Neurologists and PCPs (P8-12.011)
Finnegan, Thomas , Merlo, Kathryn, Singh, Rashmi B. Halker

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202305 Get It